Małgorzata Raś

Małgorzata Raś

Auto-generated profile, based on publicly available information

Małgorzata Raś

Provincial Specialist Hospital in Wroclaw, Poland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019
Verified
Journal Article
Open access
AJAgnieszka Jalowska
Agnieszka Jalowska
JKJoanna Krzeszowiak
Joanna Krzeszowiak
ASAgnieszka Stembalska
Agnieszka Stembalska
KSKrzysztof Szmyd
Krzysztof Szmyd
MZMariusz Zimmer
Mariusz Zimmer
RŚRobert Śmigiel
Robert Śmigiel
Lethal defects lead to the intrauterine death of the fetus or the passing away of the child immediately after birth or in early infancy, regardless of the treatment used. In the case of lethal defects, it is not possible to effectively help the child, despite using the most modern equipment or medicines in the treatment or the progress made by medicine. Parents, who decide to continue the pregnancy, although the fetus has a lethal defect that cannot be cured, may be covered by perinatal hospice care, which is comprehensive and consists in supporting the pregnant woman during the prenatal time, during delivery and after delivery and support of her family, giving full information to the parents about their child's illness. Childcare after birth is focused on protecting the infant from persistent therapy and providing him with appropriate conditions. Aim: To demonstrate the role of perinatal palliative care for pregnant women in whom the results of prenatal tests pointed to a severe developmental disorder in the fetus with a potentially lethal prognosis, and to present a pattern of behavior for their hospitalization in the perinatal hospice. Materials and methods: The retrospective analysis included documentation of 67 patients referred to the RAZEM (TOGETHER) Program in Wrocław in 2014-2018 due to abnormal results of (ultrasound and / or genetic) prenatal tests, which indicated a serious developmental disorder in the fetus with potentially lethal prognosis. Analysis was conducted of sociodemographic data, clinical data on fetal diagnosis, pregnancy and delivery, the procedure for prenatal delivery and postnatal birth. Results: 67 women aged 20-43 years (mean 31.2) were referred to the RAZEM Program. Out of these, 57 women were enrolled for palliative care, which accounted for 85% of those referred to the program. Palliative care was continued in 51 patients, because 6 women decided to terminate their pregnancy during the diagnostic process (10.5%). The most common abnormalities in the fetuses were chromosomal aberrations, CNS defects and kidney defects. In 95% of the cases, intrauterine fetal death or neonatal death occurred. Conclusions: Perinatal palliative care is an indispensable form of care for pregnant women in whom the results of prenatal tests indicate a serious developmental disorder in the fetus with potentially lethal prognosis. The in-hospital model of a perinatal hospice is a beneficial form of care, as it ensures consistency and good communication in the team, which favourably affects its quality.

2 February 2026 in Annales Academiae Medicae Silesiensis
Verified
Journal Article
Open access
HRHanna Raś
Hanna Raś
MRMałgorzata Raś
Małgorzata Raś
PKPrzemysław Kubicki
Przemysław Kubicki
KJKatarzyna Jankowska
Katarzyna Jankowska
MGMaria Greniuk
Maria Greniuk
Zespół Floating-Harbor (Floating-Harbor syndrome – FHS) to wyjątkowo rzadkie, uwarunkowane genetycznie schorzenie, charakteryzujące się niepełnosprawnością intelektualną, specyficznymi rysami twarzy i niskim wzrostem, w połączeniu z opóźnieniem wieku kostnego oraz zaburzeniami mowy. Do tej pory w literaturze opisano nieco ponad 100 przypadków pacjentów z tym zespołem. W pracy opisano przypadek 8-letniego chłopca, u którego rozpoznano FHS, a który dodatkowo choruje na nadciśnienie płucne. Starano się odpowiedzieć na pytanie, czy wada serca i schorzenia kardiologiczne u chłopca mogą być składowymi jego wady genetycznej. Ponadto poruszono problem niedoboru wzrostu u pacjentów z FHS i przedstawiono wyniki leczenia rekombinowanym ludzkim hormonem wzrostu. Z uwagi na niezwykle ograniczoną liczbę opisanych przypadków FHS artykuł może się przyczynić do poszerzenia wiedzy na temat zespołu i dokładniej zdefiniować jego fenotyp kliniczny.